Patents by Inventor Hwan Geun Choi

Hwan Geun Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220162203
    Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 26, 2022
    Inventors: Youn Ho LEE, Ju Hee KANG, Se In KANG, Yi Kyung KO, Eun Hwa KO, Hwan Geun CHOI, Jung Beom SON, Nam Doo KIM
  • Patent number: 11341043
    Abstract: A storage device includes a non-volatile memory including a plurality of memory blocks. The storage device performs an alignment operation in response to receipt of an align command. The alignment operation converts a received logical address of a logical segment into a physical address and allocates the physical address to a physical block address corresponding to a free block. The storage device is further configured to performs a garbage collection in units of the physical block address that indicates one memory block.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: May 24, 2022
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Byoung-Geun Kim, In-Hwan Doh, Joo-Young Hwang, Seung-Uk Shin, Min-Seok Ko, Jae-Yoon Choi
  • Publication number: 20220133736
    Abstract: The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: November 22, 2021
    Publication date: May 5, 2022
    Applicants: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: David E. Fisher, Nisma Mujahid, Ryo Murakami, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi
  • Publication number: 20220106307
    Abstract: The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
    Type: Application
    Filed: August 10, 2021
    Publication date: April 7, 2022
    Inventors: Hwan Geun CHOI, Eunhwa KO, Joong-heui CHO, Jung Beom SON, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Hee Yoon RYU, Nam Doo KIM, Sang Bum KIM, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Sungchan CHO, Kyu-Sun LEE, Kweon YU, Miri CHOI, Ja Wook KOO, Hyang-Sook HOE
  • Patent number: 11285158
    Abstract: The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 29, 2022
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: David E. Fisher, Nisma Mujahid, Ryo Murakami, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi
  • Publication number: 20220073505
    Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell limes, and thus can be usefully used in the treatment of lung cancer.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 10, 2022
    Applicants: VORONOI INC., B2SBIO INC., VORONOIBIO INC., B2SBIO INC.
    Inventors: Youn Ho LEE, Ju Hee KANG, Se In KANG, Yi Kyung KO, Eun Hwa KO, Hwan Geun CHOI, Jung Beom SON, Nam Doo KIM
  • Patent number: 11241435
    Abstract: The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).
    Type: Grant
    Filed: September 16, 2017
    Date of Patent: February 8, 2022
    Assignees: The General Hospital Corporation, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Marc Wein, Henry Kronenberg, Thomas Sundberg, Ramnik Xavier, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Alykhan Shamji
  • Patent number: 11208412
    Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: December 28, 2021
    Assignees: Daegu-Gyeongbuk Medical Innovation Foundation, National Cancer Center, Samsung Life Public Welfare Foundation
    Inventors: Hwan Geun Choi, Jong Bae Park, Eunhwa Ko, Jung Beom Son, Joong-heui Cho, Yi Kyung Ko, Jin-Hee Park, So Young Kim, Seock Yong Kang, Seungyeon Lee, Nam Doo Kim, Yunho Lee, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Jae Hyun Bae, Eunmi Hong, Tae-ho Jang, Sang Bum Kim, Seung Hoon Lee, Do-Hyun Nam
  • Publication number: 20210284634
    Abstract: The present invention relates to a novel compound exhibiting enteropeptidase-inhibiting activity, a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing and treating metabolic diseases such as obesity, diabetes mellitus or hyperlipidemia, etc. comprising the compound or pharmaceutically acceptable salt, and a method for preventing or treating metabolic disease using the above novel compound. The compound of the present invention has excellent inhibitory activity against enteropeptidase, and thus is not absorbed into the body, but are excreted outside the body. However, since not only fat but also protein are discharged together, it has few side effects such as fat stools and acts only in the gastrointestinal tract, so it has few side effects such as depression, and is very useful as a therapeutic or prophylactic drug for various metabolic diseases such as obesity, diabetes mellitus, and hyperlipidemia.
    Type: Application
    Filed: May 8, 2019
    Publication date: September 16, 2021
    Applicant: LG Chem, Ltd.
    Inventors: Young Kwan KIM, Ohhwan KWON, Heedong PARK, Junggyu PARK, Hwan Geun CHOI, Jung Beom SON, Eunhwa KO, So Young KIM, Seungyeon LEE, Seock Yong KANG, Yi Kyung KO, Jin-Hee PARK
  • Patent number: 11117892
    Abstract: The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 14, 2021
    Inventors: Hwan Geun Choi, Eunhwa Ko, Joong-heui Cho, Jung Beom Son, Yi Kyung Ko, Jin-Hee Park, So Young Kim, Seock Yong Kang, Seungyeon Lee, Hee Yoon Ryu, Nam Doo Kim, Sang Bum Kim, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Sungchan Cho, Kyu-Sun Lee, Kweon Yu, Miri Choi, Ja Wook Koo, Hyang-Sook Hoe
  • Publication number: 20210267997
    Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of brain cancer, containing a compound capable of penetrating the blood-brain barrier as an active ingredient, the pharmaceutical composition for the prevention or treatment of brain cancer is capable of efficiently penetrating the blood-brain barrier of the brain to thereby effectively inhibit LRRK2 protein expression, and is thus useful in the prevention or treatment of brain cancer.
    Type: Application
    Filed: February 23, 2018
    Publication date: September 2, 2021
    Inventors: Hwan Geun Choi, Jong Bae Park, Eunhwa Ko, Jung Beom Son, Nam Doo Kim, Seung Hoon Lee, Do-Hyun Nam
  • Publication number: 20210147425
    Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind C protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: November 20, 2020
    Publication date: May 20, 2021
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Thomas Sundberg, Alykhan Shamji, Ramnik Xavier, David E. Fisher, Nisma Mujahid
  • Publication number: 20210147388
    Abstract: The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 20, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Hwan Geun Choi, Yanke Liang
  • Publication number: 20210115055
    Abstract: Compounds having the formula I, II, or III: are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 22, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher, Hwan Geun Choi
  • Patent number: 10975058
    Abstract: The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 13, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Hwan Geun Choi, Yanke Liang
  • Publication number: 20210094913
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: September 28, 2020
    Publication date: April 1, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. GRAY, Michael ECK, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG, Kwok-Kin WONG
  • Patent number: 10954242
    Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: March 23, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Thomas Sundberg, Alykhan Shamji, Ramnik Xavier, David E. Fisher, Nisma Mujahid
  • Publication number: 20210078977
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 18, 2021
    Inventors: Nathanael S. GRAY, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG
  • Patent number: 10913744
    Abstract: Compounds having the formula I, II, or III: are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: February 9, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher, Hwan Geun Choi
  • Patent number: 10875844
    Abstract: Provided herein are small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK) having the structure of formula (I), wherein X and R1-R3 are defined in the specification. The compounds are useful for treating cancer and other conditions or diseases associated with aberrant MELK expression. Also provided herein are pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The invention also provides methods of treating cancers associated with over-expression of MELK.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: December 29, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Tinghu Zhang, Hai-Tsang Huang, Yubao Wang, Jean Zhao, Hwan Geun Choi